Boston biotech Atalanta raises $97M to bring CNS drugs into clinic
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
FierceBiotech11h
Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
TJX buys two office buildings near its Framingham HQ
TJX has purchased a pair of office buildings a short distance from its Framingham headquarters for $24.3 million.
The MetroWest Daily News13h
Why Mayor Charlie Sisitsky, in his State of the City, said Framingham is 'strong'
Framingham Mayor Charlie Sisitsky delivered his fourth State of the City address Monday evening at Nevins Hall.